Analyst Research

Report Title Price
Provider : Reuters Investment Profile
Provider : Edison Investment Research

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Islet Sciences Inc announces positive 12-Week phase 2 clinical results for SGLT2 Inhibitor Remogliflozin Etabonate

Wednesday, 16 Apr 2014 12:16pm EDT 

Islet Sciences Inc:Positive results from two 12-week phase 2b clinical studies of remogliflozin etabonate in type 2 diabetics.Primary end point was HbA1c with secondary end points of fasting plasma glucose, serum lipids, body weight, safety and tolerability.Remogliflozin etabonate is selective SGLT2 inhibitor indicated for type 2 diabetes and NASH.Both phase 2b studies were multicenter, randomized, double-blind, placebo-controlled, pioglitazone-controlled, parallel-group, dose-ranging.Studies evaluating efficacy, safety, and tolerability of multiple remogliflozin etabonate doses for 12 weeks in treatment-na├»ve subjects with type 2 diabetes.One study dosed remogliflozin etabonate once-daily and the other dosed remogliflozin etabonate twice-daily over the twelve week study period. 

Company Quote

27 Aug 2015